Compare Biocon with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs FULFORD INDIA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON FULFORD INDIA BIOCON /
FULFORD INDIA
 
P/E (TTM) x 34.9 398.8 8.8% View Chart
P/BV x 4.4 6.2 71.2% View Chart
Dividend Yield % 0.2 0.1 262.7%  

Financials

 BIOCON    FULFORD INDIA
EQUITY SHARE DATA
    BIOCON
Mar-19
FULFORD INDIA
Mar-14
BIOCON /
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs707942 75.1%   
Low Rs554450 123.1%   
Sales per share (Unadj.) Rs91.9691.4 13.3%  
Earnings per share (Unadj.) Rs16.711.5 145.8%  
Cash flow per share (Unadj.) Rs24.215.4 157.4%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.3 55.2%  
Book value per share (Unadj.) Rs101.6380.0 26.7%  
Shares outstanding (eoy) m600.003.90 15,384.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.91.0 681.5%   
Avg P/E ratio x37.760.7 62.1%  
P/CF ratio (eoy) x26.145.3 57.6%  
Price / Book Value ratio x6.21.8 338.7%  
Dividend payout %6.017.4 34.3%   
Avg Mkt Cap Rs m378,3302,714 13,937.9%   
No. of employees `0006.10.4 1,380.9%   
Total wages/salary Rs m11,653505 2,307.5%   
Avg. sales/employee Rs Th8,994.36,073.0 148.1%   
Avg. wages/employee Rs Th1,900.71,137.4 167.1%   
Avg. net profit/employee Rs Th1,635.3100.7 1,624.3%   
INCOME DATA
Net Sales Rs m55,1442,696 2,045.1%  
Other income Rs m1,444125 1,151.5%   
Total revenues Rs m56,5882,822 2,005.4%   
Gross profit Rs m15,883-46 -34,230.6%  
Depreciation Rs m4,47815 29,460.5%   
Interest Rs m70910 7,463.2%   
Profit before tax Rs m12,14054 22,357.3%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,12310 22,114.6%   
Profit after tax Rs m10,02645 22,429.5%  
Gross profit margin %28.8-1.7 -1,673.8%  
Effective tax rate %17.517.7 98.9%   
Net profit margin %18.21.7 1,096.7%  
BALANCE SHEET DATA
Current assets Rs m48,2281,738 2,774.4%   
Current liabilities Rs m30,376545 5,576.6%   
Net working cap to sales %32.444.3 73.1%  
Current ratio x1.63.2 49.8%  
Inventory Days Days6848 140.9%  
Debtors Days Days864 1,986.3%  
Net fixed assets Rs m64,13012 538,907.6%   
Share capital Rs m3,00039 7,692.3%   
"Free" reserves Rs m57,9801,443 4,018.0%   
Net worth Rs m60,9801,482 4,114.7%   
Long term debt Rs m15,7660-   
Total assets Rs m121,9242,077 5,871.0%  
Interest coverage x18.16.7 269.9%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.3 34.8%   
Return on assets %8.82.6 337.4%  
Return on equity %16.43.0 545.1%  
Return on capital %16.84.3 389.2%  
Exports to sales %28.10-   
Imports to sales %18.924.5 77.1%   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399659 1,577.3%   
Fx inflow Rs m15,50617 90,151.2%   
Fx outflow Rs m10,399673 1,544.8%   
Net fx Rs m5,107-656 -778.6%   
CASH FLOW
From Operations Rs m11,54690 12,828.9%  
From Investments Rs m-7,138105 -6,824.1%  
From Financial Activity Rs m-2,417-14 17,141.8%  
Net Cashflow Rs m2,103181 1,165.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 3.8 221.1%  
FIIs % 10.7 0.1 10,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.2 93.9%  
Shareholders   109,995 4,783 2,299.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALEMBIC  SUN PHARMA  IPCA LABS  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Dow Futures Up by 6 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 20, 2021 03:36 PM

TRACK BIOCON

BIOCON - GSK PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS